BioVaxys and Adiverna Collaborate on AI-Designed mRNA Vaccines for Companion Animals

BioVaxys Technology Corp. and Adiverna LLC have entered into a Research Agreement to develop mRNA-based vaccines for rabies, leptospirosis, feline infectious peritonitis, and other diseases for companion animal veterinary applications. The collaboration combines BioVaxys' DPX™ Immune Educating Platform with Adiverna's proprietary artificial intelligence technology to design mRNA sequences coding for protective antigens. Currently, no mRNA vaccines are approved for these animals, making this partnership potentially groundbreaking in veterinary healthcare.

Adiverna's AI platform utilizes machine learning algorithms and advanced bioinformatics to analyze extensive datasets, identifying and predicting the most effective mRNA sequences that code for protective broadly cross-neutralizing antigens. This approach offers significant dose-sparing potential, reducing the amount of vaccine required while still eliciting robust immune responses. Kirill Kalnin, PhD, Founder and Chief Technology Officer of Adiverna, stated that the collaboration aims to revolutionize routine annual vaccinations for dogs and cats, enhancing their safety and effectiveness while reducing the financial burden on pet owners.

BioVaxys' DPX platform presents a novel non-systemic mechanism of action that forces active uptake of immune cells and delivery into lymphatic nodes, programming immune cells in vivo to mimic natural immune system function. This "no release" mechanism allows for sustained activation of the immune system with T cell flow sustained over longer durations than traditional vaccines. Kenneth Kovan, President and Chief Operating Officer of BioVaxys, explained that DPX provides enhanced stability of packaged mRNA and attracts a therapeutically unique subset of Antigen Presenting Cells to the injection site for targeted uptake.

Traditional vaccines for companion animals are generally effective for either one year or three years, depending on specific products and regulations. While current rabies vaccines usually last one year, subsequent boosters can be labeled for three years of protection. A DPX-formulated mRNA vaccine would offer significant advantages by delivering superior, longer-lasting immunity with fewer doses, together with high-level, rapid, and durable neutralizing antibody responses. Such vaccines would not use viral material and would have fewer impurities, reducing risks associated with injecting foreign, inactivated viruses.

The global rabies veterinary vaccines market for inactivated and modified-live virus vector products is valued at US$785 million in 2024, projected to reach approximately US$1.1 billion by 2030, growing at a 5.8% CAGR. Annual sales for canine leptospirosis killed vaccine formulations are part of the broader dog vaccine market, valued at approximately $2.10 billion in 2025. The FIV vaccine market is part of the broader feline vaccines sector, projected to reach USD 3.28 billion by 2034, growing from USD 1.77 billion in 2025. Market growth is driven by mandatory pet vaccinations, increasing disease awareness, and rising pet ownership, with North America dominating companion animal vaccination and the Asia/Pacific region experiencing rapid growth.

Kovan added that data from proof-of-concept studies of DPX-mRNA formulations demonstrate that DPX provides enhanced stability and induces specific immune responses toward encoded antigens. The collaboration represents what could be the world's first mRNA veterinary vaccine, with demonstrated in vivo proof of concept of DPX mRNA formulations potentially advancing partnering discussions for human therapeutic applications. Research supporting market projections includes reports from Research & Markets, Fortune Business Insights, Cornell University College of Veterinary Medicine, and DelveInsight.